Glucosamine Supplements Accelerate Dementia Progression and Increase Mortality Risk

Glucosamine Supplementation Accelerates Cognitive Decline and Mortality in Dementia Patients

The study, led by TR Hawkinson and colleagues and published in Nature Metabolism (2026;8:1410-1425), evaluated how metabolic precursors influence neurodegeneration. Researchers discovered widespread accumulation of complex N-glycans across vulnerable brain regions, including the cortex and hippocampus. As neurodegeneration advanced through progressive Braak stages within human gray matter, this abnormal glycosylation became more intense, draining essential biosynthetic precursors like glucosamine-6-phosphate. Through glycoproteomic profiling, scientists revealed that this pathway primarily modifies pre-existing neuronal membrane proteins vital for synaptic communication instead of creating entirely new glycoproteins.

Stable Carbon Isotope Tracing and Metabolic Flux Analyses

By employing metabolic flux analyses together with stable carbon isotope tracing, investigators verified that the disease state is propelled by elevated de novo glycan synthesis rather than any failure in lysosomal recycling. Enzymes within the hexosamine biosynthetic pathway showed significant transcriptomic upregulation in both human patients and transgenic mice. By utilizing experimental genetic knockdown targeting phosphoglucomutase 3 or chemical inhibition directed at the oligosaccharyltransferase complex, researchers successfully lowered abnormal glycan levels and restored social recognition memory in preclinical models. These therapeutic gains occurred without reducing beta-amyloid plaques, tau pathology, or reactive astrogliosis, highlighting glycan metabolism as an independent therapeutic target.

Real-World Human Data Reveal Severe Risks in Dementia Cohorts

Given that oral glucosamine crosses the blood-brain barrier with ease to supply the hexosamine pathway, scientists set out to examine its direct effects on neurodegeneration. When transgenic Alzheimer’s disease mice received daily oral glucosamine, they experienced worse cognitive deficits and increased cerebral N-glycan accumulation. To broaden their inquiry using real-world human evidence, the team analyzed electronic health records originating from upwards of 24,000 dementia patients alongside 41,000 individuals diagnosed with mild cognitive impairment. Among dementia patients, recorded use of glucosamine corresponded to a 25% elevation in mortality risk, accompanied by a 25% faster rate of transitioning from mild cognitive impairment into full dementia.

• Daily oral glucosamine intake was linked to a 25% higher mortality risk among dementia patients and a 25% increased rate of progression from mild cognitive impairment to full dementia.
• Postmortem tissue and mouse models revealed that abnormal brain hyperglycosylation alters pre-existing neuronal membrane proteins essential for synaptic communication.
• Experimental genetic knockdown and chemical inhibition successfully reduced aberrant glycan levels and restored memory in preclinical models without altering beta-amyloid plaques.

Cognitive Resilience in Healthy Models Versus Vulnerable Brains

In contrast, wild-type mice with intact cognition displayed metabolic tolerance toward glucosamine, showing neither increased glycan levels nor memory deficits. These findings indicate that glucosamine poses unique risks in the context of existing neurodegeneration, showing that clinicians must monitor over-the-counter supplement use.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.